KOSPIRetail & Consumer118000

Metacare

₩797▼ 0.99%2026-11-18 close
Market Cap
₩17.6B
Turnover
₩25,917,902
Volume
30K
Shares out.
22.1M
PER
—
PBR
0.1×
EPS
-₩115
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Metacare: Quarterly Profit Recovery Meets Balance-Sheet Tests

Metacare's operating profit has risen for two straight quarters since its first-quarter 2026 low, but weaker 2025 profitability, a cumulative net loss over the last four quarters and a KRX managed-issue designation remain open items.

  1. 1

    Operating profit for the third quarter of 2026 was KRW 1.14 billion, up 863.8% year on year, on revenue of KRW 19.4 billion, up 122.0% from the prior quarter.

  2. 2

    Full-year 2025 revenue rose 62.4% to KRW 32.8 billion, but operating profit fell 12.0% to KRW 1.32 billion, leaving an operating margin of 4.0%.

  3. 3

    The cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 2.31 billion, shaped largely by a KRW 3.72 billion loss in the fourth quarter of 2025.

  4. 4

    Because listed market capitalization stayed below KRW 30 billion, KRX designated the stock as a managed issue; trading was halted on October 29, 2026 and resumed on October 30.

  5. 5

    A correction filing on November 16, 2026 cut third-quarter 2026 consolidated net income to KRW 449 million from KRW 1.34 billion, according to press reports.

02

Business structure

Metacare was split off from the medical division of a pharmaceutical company in 2009 and operates from its Hwaseong headquarters across pharmaceutical distribution, hair-transplant clinic management consulting, real estate development and advertising agency services.

According to a Money Today report dated October 6, 2026, first-half 2026 revenue mix was 46.4% consulting, 37.0% pharmaceuticals, 8.5% medical and 8.1% real estate development.

The pharmaceutical arm supplies prescription drugs, medical devices and medical consumables through a proprietary distribution network built through M&A.

The consulting arm rests mainly on management consulting contracts with hair-transplant specialty hospitals, while the company's earnings commentary credits a pharmaceutical distributor acquisition with strengthening purchasing power. The subsidiary base has also widened.

Metacare bought all shares of a real estate developer in 2024 and in 2026 consolidated an ad-tech subsidiary, extending into advertising agency and ad-tech services.

A wholly owned distribution subsidiary was acquired for KRW 360 million on July 27, 2026 and merged into Metacare with an effective date of October 1, 2026.

In hair care, the company is preparing a low-dose dutasteride 0.2mg product, with contract manufacturing from a pharmaceutical partner and sales through distribution channels it already holds.

On the customer side, reports describe plans to use more than 200,000 customer records accumulated through clinic consulting and hair-care solutions across a platform linking patient intake to aftercare. The largest shareholder is Metalabs.

A June 2026 filing on a KRW 6 billion third-party allotment rights issue said its stake would rise from 37.28% to 51.78%, while an October 2026 report cited 29.04%, so the reference dates should be checked.

Against larger drug distributors, direct scale comparison is difficult, and the hospital management-support segment is closer to a niche business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.8B₩100M1.1%
2025Q4₩10.3B-₩100M−1.4%
2026Q1₩10.1B₩600M5.7%
2026Q2₩8.8B₩800M9.1%
2026Q3₩19.4B₩1.1B5.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩19.1B-₩300M-₩49.6B−1.6%−49.9%46.5%
2023₩55.8B-₩8.9B-₩14.5B−16.0%−13.7%12.8%
2024₩20.2B₩1.5B₩9.3B7.4%8.0%35.5%
2025₩32.8B₩1.3B₩500M4.0%0.4%63.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 19.1 billion in 2022 to KRW 55.8 billion in 2023, and 2023 was the largest year in the 2022 to 2025 span. Revenue fell 63.8% year on year to KRW 20.2 billion in 2024 and then rose 62.4% to KRW 32.8 billion in 2025.

Operating losses of KRW 300 million in 2022 and KRW 8.9 billion in 2023 reflected continued losses with a widening deficit in 2023, before operating profit of KRW 1.5 billion in 2024 marked a turn to profit.

Operating profit fell 12.0% to KRW 1.32 billion in 2025, and the operating margin slid from 7.4% in 2024 to 4.0%. Net income attributable to controlling shareholders swung to KRW 9.28 billion in 2024 and fell 94.6% to KRW 498 million in 2025.

The 2025 net loss of KRW 212 million differs from that figure because non-controlling interests posted a loss, as FnGuide's financial summary shows.

Debt-to-equity rose to 63.6% at the end of 2025 from 35.5% in 2024, with total liabilities of KRW 77 billion against total equity of KRW 121 billion, of which KRW 119.4 billion belongs to controlling shareholders.

Operating cash flow moved from negative KRW 12.9 billion in 2023 to positive KRW 4.48 billion in 2024 and KRW 2.42 billion in 2025.

Quarterly, operating profit of KRW 119 million in the third quarter of 2025 was followed by an operating loss of KRW 143 million in the fourth quarter, when net loss attributable to controlling shareholders reached KRW 3.72 billion.

In the first quarter of 2026, revenue was KRW 10.1 billion and operating profit KRW 577 million, a turn back to profit. Second-quarter 2026 revenue of KRW 8.76 billion fell 13.4% from the prior quarter, yet operating profit rose 38.1% to KRW 796 million.

Third-quarter 2026 revenue reached KRW 19.4 billion, up 122.0% from the prior quarter and 80.9% year on year, with operating profit of KRW 1.14 billion, up 43.7% from the prior quarter and 863.8% year on year. Operating profit has risen for two straight quarters from the first-quarter 2026 low.

The 2026 consolidation of an ad-tech subsidiary is cited as part of the revenue jump, but its quarterly contribution needs to be checked in filing detail.

A November 16, 2026 correction cut third-quarter consolidated net income from KRW 1.34 billion to KRW 449 million, which press reports attributed to accounting adjustments for newly consolidated and liquidated entities.

05

Industry analysis

In hair-loss treatment, dutasteride has been used mainly at the 0.5mg standard approved dose, while the 0.2mg low-dose product is presented as keeping effect at a set level while lowering drug exposure, according to a Money Today report dated October 6, 2026.

Whether demand for low-dose options converts into actual prescriptions is hard to gauge from press reports alone, and the market size cannot be quantified from the available sources.

The pharmaceutical distribution arm is exposed to hospital demand and drug pricing policy, and the plan to link general-hospital GPO business with hair-care drugs is presented as its growth path.

Hospital management consulting rests on contracts with hair-transplant specialty hospitals, so results can swing with the number and terms of those counterparties. Advertising agency and ad-tech operations are sensitive to advertising spend.

Unlike consumer rental businesses such as Coway, Metacare's weight sits on hospital-facing B2B services and pharmaceutical distribution.

A cycle position cannot be shown with a quantitative indicator, and within its sector the company's position rests more on the combination of hospital services and hair-care drugs than on scale.

06

Outlook

On October 21, 2026, the board approved a 2026 corporate value-up plan.

Its targets are improving the profit structure, restoring financial stability and laying the groundwork for shareholder returns, with execution tasks covering liquidity stabilization, profit-structure improvement with growth foundations, and shareholder value.

The plan includes a PBR improvement measure, and its details may change with market and business conditions. The first business test is sales of the low-dose dutasteride 0.2mg product, whose contribution to results can first be gauged in the provisional fourth-quarter 2026 results expected in early 2027.

The plan also links general-hospital GPO business with hair-care drugs to expand supply of pharmaceuticals and medical consumables. The merger of the wholly owned distribution subsidiary, effective October 1, 2026, simplifies the distribution structure.

The company said proceeds from the KRW 6 billion rights issue announced in June 2026 would be used for acquiring shares of other companies, and the target and size will become clear when individual disclosures are filed.

Whether the first-half 2026 run-rate of KRW 18.9 billion in revenue and KRW 1.4 billion in operating profit continued through the third quarter can be checked against the quarterly figures already filed.

The 2026 annual report, due by March 31, 2027, is the next benchmark for annual operating margin, net income attributable to controlling shareholders and progress on the value-up plan.

07

Valuation

PER
—
PBR
0.1×
ROE
-1.9%
EPS
-₩115
BPS
₩6,580
Dividend per share
₩0

Because the last four quarters include a net loss attributable to controlling shareholders, a price-to-earnings ratio cannot be calculated. Quarterly profits have continued since 2026, but the fourth-quarter 2025 loss remains inside the four-quarter window, so an earnings-based multiple is not computed.

On a book-value basis, the stock trades well below net asset value per share. Because the value-up plan explicitly targets the PBR, the relationship between share price and asset value is a stated management priority. The dividend yield is around zero, so a dividend-based yield comparison does not apply.

A historical PER band is hard to read because profit and loss alternated. The stock was designated a managed issue in October 2026 after listed market capitalization stayed below the KRW 30 billion threshold, a market-rule requirement directly tied to market value. Valuation is best read by placing business metrics and listing requirements side by side.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Recovery in quarterly operating profit

Operating profit rose from KRW 577 million in the first quarter of 2026 to KRW 796 million in the second and KRW 1.14 billion in the third, two straight quarters of gains. Third-quarter revenue of KRW 19.4 billion, up 122.0% from the prior quarter, shows the top line expanded alongside. How far the operating margin has climbed from 4.0% in 2025 will be checked in the 2026 annual report.

Business expansion and product pipeline

The low-dose dutasteride 0.2mg product is planned for sale through existing distribution channels, produced under a contract manufacturing agreement. The company intends to pair GPO business at general hospitals with hair-care drugs and to link more than 200,000 customer records to patient care. The revenue contribution of the new product will be gauged from quarterly filings after launch.

Largest-shareholder support and funding

In June 2026, a KRW 6 billion third-party rights issue was set for the largest shareholder, Metalabs, which the company described as a sign of the shareholder's commitment. The proceeds are planned for acquiring shares of other companies.

On October 21, 2026, a value-up plan covering liquidity stabilization and profit-structure improvement was approved.

09

Bear factors

Weaker annual profitability in 2025

Revenue rose 62.4% in 2025, but operating profit fell 12.0% to KRW 1.32 billion and the operating margin dropped to 4.0% from 7.4% in 2024. Net income attributable to controlling shareholders fell 94.6% to KRW 498 million. Sales growth did not translate into higher profit that year.

Quarterly swings and correction

The fourth quarter of 2025 posted an operating loss of KRW 143 million and a KRW 3.72 billion net loss attributable to controlling shareholders, leaving a four-quarter cumulative loss of KRW 2.31 billion. A November 16, 2026 correction reportedly cut third-quarter consolidated net income to KRW 449 million. Quarterly earnings direction has shifted within short periods.

Listing requirements and trading constraints

After listed market capitalization stayed below KRW 30 billion for 25 trading days, KRX warned of a managed-issue designation in October 2026. The designation and a trading halt from October 29 were announced on October 28, and trading resumed at 9:00 on October 30. A managed-issue status directly affects trading conditions.

10

Risk factors

Earnings volatility and correction risk

Quarterly operating profit swung from KRW 119 million in the third quarter of 2025 to a loss in the fourth quarter and KRW 1.14 billion in the third quarter of 2026. A correction reportedly cut third-quarter net income to KRW 449 million from KRW 1.34 billion.

Because changes in consolidated entities and accounting adjustments affect quarterly figures, the possibility of further restatement needs to be watched.

Balance sheet and funding

Debt-to-equity rose to 63.6% at the end of 2025 from 35.5% in 2024. Operating cash flow stayed positive, but at KRW 2.42 billion in 2025 it was modest. Proceeds from the KRW 6 billion rights issue are slated for acquisitions of other companies, so the financial burden could change if deal sizes grow.

Business concentration and launch risk

Revenue relies heavily on consulting and pharmaceuticals, and consulting depends on contracts with hair-transplant hospitals. The low-dose dutasteride product depends on contract manufacturing and existing channels, so sales pace could differ from plans.

The largest shareholder's stake is cited as 51.78% after the rights issue in a June 2026 filing and 29.04% in an October 2026 report, so the ownership base should be confirmed.

11

What to watch next

  1. Early 2027 (expected timing of Q4 2026 provisional results)

    The checkpoints are how much low-dose dutasteride sales are reflected in fourth-quarter results and whether operating profit holds near the KRW 1.14 billion of the third quarter of 2026.

  2. March 31, 2027 (filing deadline for the 2026 annual report)

    The next filing's checkpoints are full-year 2026 revenue, operating margin, net income attributable to controlling shareholders, whether the third-quarter correction is reflected, and the change in debt-to-equity.

  3. Ongoing (at KRX disclosure timing)

    Items to watch are whether listed market capitalization meets the threshold and any change in the managed-issue status. Continued failure to meet the threshold keeps the listing-requirement risk in place.

  4. Ongoing (at disclosure of acquisitions of other companies)

    The next checkpoint is the use of the KRW 6 billion rights issue proceeds, along with the target and size of any acquisition once disclosed.

12

Overall view

Metacare grew 2025 revenue to KRW 32.8 billion, but operating profit fell to KRW 1.32 billion and net income attributable to controlling shareholders to KRW 498 million. In 2026, operating profit has risen for two straight quarters since the first-quarter turn to profit, showing a recovery in quarterly earnings.

How much the consolidation of a new entity contributed to third-quarter revenue of KRW 19.4 billion, and the level of corrected net income, need to be confirmed in upcoming filings.

The business spans consulting, pharmaceuticals, medical and real estate development, with plans for a low-dose hair-loss drug and GPO linkage at general hospitals.

On the balance sheet, debt-to-equity rose to 63.6% at the end of 2025, and a cumulative four-quarter loss attributable to controlling shareholders of KRW 2.31 billion remains.

On the listing side, the company went through a managed-issue designation and trading halt in October 2026, and its value-up plan names liquidity stabilization and profit-structure improvement as tasks.

Positive factors are the quarterly profit recovery, business diversification and support from the largest shareholder. Negative factors are weaker annual profitability, restated quarterly results and an unmet listing requirement.

The 2026 annual report, with full-year operating margin and net income attributable to controlling shareholders, will show more clearly how these factors balance.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. comp.fnguide.com
  4. comp.fnguide.com
  5. digitaltoday.co.kr
  6. news.nate.com
  7. digitaltoday.co.kr
  8. vegannews.co.kr
  9. view.asiae.co.kr
  10. vegannews.co.kr
  11. vegannews.co.kr
  12. topstarnews.net
  13. digitaltoday.co.kr
  14. mt.co.kr
  15. topstarnews.net
  16. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis